- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Foundation for the National Institutes of Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast, Cancer of Prostate, Cancer Colorectal, Cancer, Endometrial, Cancer of Head and Neck, Non Small Cell Lung Cancer, CVD - Cardiovascular Disease, Diabetes Mellitus, Hypercholesterolemia, Diabetes, Cancer of Esophagus, Cancer of Liver, Cancer, Renal Cell, Cancer of Pancreas, Cancer Ovaries
- Interventions
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Resectable Head and Neck Squamous Cell Carcinoma
- Interventions
- 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
- Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab, BYL719 drink suspension
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Cancer of Head and Neck, Smoking
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Interventions
- vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
- Interventions
- ixabepilone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- MT-6402
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
- Conditions
- Thyroid Cancer
- Interventions
- Avutometinib, Defactinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Oral Cavity Neoplasm
- Interventions
- High-Resolution Microendoscopy, Multispectral Imaging, Proflavine
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Breast Cancer, Brain Cancer, Central Nervous System Cancer, Colorectal Cancer, Esophageal Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Melanoma, Blood Cancer, Lung Cancer, Acceptance and Commitment Therapy, Mind-Body Therapies, Psychosocial Intervention
- Interventions
- Mind Over Matter (MOM)
- Other
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Fairfax, Virginia
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Pamiparib, Temozolomide
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more
- Conditions
- Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
- Interventions
- NIRAF Detection Technology
- Device
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HPV-positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Robotic surgery
- Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 2
- States / cities
- Paramus, New Jersey • New York, New York
- Conditions
- Gastroesophageal Reflux Disease, Esophageal Cancer, Barrett's Esophagus
- Interventions
- Decision Aid
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Oral Leukoplakia
- Interventions
- rosiglitazone maleate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
- Interventions
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
- Drug
- Lead sponsor
- Kineta Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer
- Interventions
- Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 1,559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
- Interventions
- ISA101b, Cemiplimab, Placebo
- Biological · Drug · Other
- Lead sponsor
- ISA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 10
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 7 more
- Conditions
- Recurrent Head and Neck Cancer
- Interventions
- PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2, PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2
- Combination Product
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
- Interventions
- Docetaxel, Cisplatin, PRGN-2009
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- AT-101, Docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
- Interventions
- Cabiralizumab, Nivolumab
- Biological
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more